The FDA assigned an April 9, 2027, target action date to resubmitted applications for rivoceranib plus camrelizumab in unresectable or metastatic hepatocellular carcinoma.
|Articles|September 1, 2006
- ONCOLOGY Vol 20 No 10
- Volume 20
- Issue 10
Wall Chart Featuring Skin-Related Toxicities of Targeted Therapies
Wall Chart Featuring Skin-Related Toxicities of Targeted Therapies
Advertisement
Download the wall chart of Skin-Related Toxicities of Targeted Therapies as a PDF.
Articles in this issue
about 20 years ago
Complete Guide to Colorectal Cancerabout 20 years ago
Decitabine Receives US Orphan Drug Designation for AMLabout 20 years ago
New Questions About Transplantation in Multiple Myeloma: Review 1about 20 years ago
FDA Approves Drug Combination for Ovarian Cancer Recurrenceabout 20 years ago
Stage III Lung Cancer: Two or Three Modalities? Review 1Advertisement
Related to this article
Adam C. Olson, MD, MSc-GH, discussed letting patients choose between modalities with comparably strong evidence, and the data that shaped his approach.
Data from the phase 3 MANGROVE study support the application for zanubrutinib/rituximab in this mantle cell lymphoma population.
Sunnie Kim, MD, discussed perioperative durvalumab plus FLOT, ctDNA-guided de-escalation, irAE monitoring, and biomarkers in gastroesophageal cancer.
Adam C. Olson, MD, MSc-GH, discussed the infrastructure, training, and shared decision-making behind building a prostate HDR brachytherapy program.
In HypoMast-IMNI, 16-fraction PMRT with internal mammary node irradiation matched conventional RT for locoregional control with less grade 3 skin toxicity.
In the phase 2 DALY 2-EU trial, zamto-cel prolonged median event-free survival vs R-GemOx in transplant-ineligible relapsed/refractory large B-cell lymphoma.
In a phase 2 trial, CD38-targeted immune-PET detected active multiple myeloma in some patients with no signs of disease on standard fluorodeoxyglucose PET/CT.
Advertisement
Advertisement
Trending on CancerNetwork
1
CD38-Targeted Immuno-PET Helps Detect Active Multiple Myeloma
2
Biomarker Sequencing, PD-L1 Status, and FLOT Dosing in Gastroesophageal Cancer
3
Setting Up an HDR Brachytherapy Program Amid a National Decline
4
Zamto-Cel Improves EFS vs R-GemOx in Transplant-Ineligible R/R LBCL
5